Correct srin!
I still hold a substantial amount in CD's....
Interest, at 8% is also paid in shares at time of conversion.....
The attractors are obvious - If one firmly believes in the product pipeline of BIEL, its IP (multiple patents USPTO), its potential market share in the global pain space for the many indications which ActiPatch, RecoveryRx and Allay have successfully treated drug-free and with no side-effects, distributors in >50 countries, UK NHS national insurance coverage - England, Ireland, Scotland and Wales, U.S. potential in all aspects of pain management - VA, the Blues, HMO's, hospitals, clinics, dentists, B. Braun UK and USA, then one would agree that BIEL presents a substantial business case for investment.
Now, consider co-Branding opportunities and the future of ActiPatch on the shelves of the major pharma players in the U.S., the only unknown of course being which will be first....and a substantial business case is elevated to the realm of formidable, in my opinion.
If a substantial global co-Branding partner can invest a few million every year for 3-5 years on the 'Branding' journey, plus one or more major U.S. pharma chains get on board the drug-free, side-effect free wave that is coming, to combat the drug abuse and opioid epidemic, now do the calculations of market share %, sales, profits, market cap.....Branding, sales growth....5 years.....it gets crazy!
If I owned BIEL, I would do a lucrative co-Branding LA with the usual up-front and royalty considerations plus a large U.S. retailer pharma deal, with no exclusives, unless very large dollars were involved, and I certainly would not sell any of my cleared 510(K)'s, now common in the pharma industry, because that is selling 100% of one or more indication clearances.....never, ever sell a 510(K) because you just sold 100% of that segment of your IP, 100% of that slice of your company.....
It doesn't take a genius to assess that the value of the IP and potential market share of BIEL is well north of a billion dollars. Can BIEL realize that potential on it's own? Of course not and anyone who absurdly suggests they can should check into rehab. BUT the reality is also that the big players in the global pain space cannot corner this pain space disruptive technology without BIEL and BIEL cannot corner it without them, thus it calls for a fair deal for all parties! I've laughed when some kick around numbers like $250 and $500 million for even a small portion of BIEL.....nonsense!
Calculate 50 million ActiPatches annually at a profit of $5-$8, then apply a cap rate....adjust to taste allowing for growth over the nex 20 years and re-do your calculations. Now factor in that one of the major players in the pain space will want to be first! I would be talking to several......
It's for all the above reasons that I concluded it is better to invest in the revolving convertible loan model at a below current market price per share and earn 8% on the loan while invested.
BIEL.....imminent co-Branding and U.S. retail pharma deal Tsunami....
